 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Miravant Medical Technologies
 |
Miravant Medical Technologies |
 |
 |
 |
PROFILE |
 |
Miravant Medical Technologies wants to shed a little light on diseases in such fields as oncology and ophthalmology. Miravant is using its proprietary PhotoPoint technologies to develop drugs and devices for use in photodynamic therapy, a medical technology that uses light to activate drugs. The company's main focus is age-related macular degeneration (AMD), a condition that causes blood vessels to grow abnormally under the surface of the retina, leading to blindness. Miravant and partners Pharmacia, which owns about 12% of the company, and IRIDEX are developing lead product candidate SnET2 for AMD. SnET2 may also treat cardiovascular diseases, cancer, and dermatology conditions.
COMPETITION |
 |
DUSA Pharmaceuticals, Inc. (DUSA)
Photogen Technologies, Inc. (PHGN)
QLT Inc. (QLTI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 4.60
1-Yr. Sales Growth: (68.5)%
Employees: 144
Revenue per employee: $31,944.44
KEY PEOPLE |
 |
Gary S. Kledzik
CEO
John M. Philpott
CFO
CONTACT INFO |
 |
336 Bollay Dr.
Santa Barbara, CA 93117
US
Phone: 805-685-9880
Fax: 805-685-2959
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |